The new WHO classification of central nervous system tumors in 2016 added molecular features to the histological basis and renamed them using histological and molecular features; for example, glioma can be classified into IDH-mutant and wild-type based on the IDH gene mutation. This evidence concerns the gene IDH1 and glioma.